Braveheart Bio (BRVE) vs COMPASS Pathways Plc American Depository Shares (CMPS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.62 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | CMPS |
|---|---|---|
| Share price | $18.58 | $11.69 |
| Market cap | $1.67B | $1.62B |
| 1-day change | -6.11% | +1.12% |
| YTD return | — | +69.42% |
| 1-year return | — | +87.34% |
| 5-year return | — | -63.72% |
| EPS (TTM) | $-6.08 | $-3.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $15.87 |
| 52-week low | $18.47 | $4.88 |
| Distance from 52-week high | -41.94% | -26.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.54% | +103.17% |
| Average volume | 567.47K | 3.13M |
| Shares outstanding | 90.04M | 138.48M |
| Employees | 49 | 156 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
BRVE vs CMPS FAQ
Which is bigger, Braveheart Bio or COMPASS Pathways Plc American Depository Shares?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.62B for COMPASS Pathways Plc American Depository Shares (CMPS).
Are Braveheart Bio and COMPASS Pathways Plc American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.